CRL for oxylanthanum carbonate (Jun 30 2026) — third-party manufacturing (same as 2025); no efficacy/safety issues
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/12/26) through T+5. Run-up high $8.56 on 5/18/26, low $5.52 on 1/12/26 (T-120 to T-1). FDA decision 6/29/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-29
OutcomeCRL
Drug / candidateOxylanthanum Carbonate (OLC)
IndicationKidney disease
CompanyUnicycive Therapeutics
Market-cap tierMicro
120-day run-up (T-120→T-1)+29.2%
Cohort decision-day move (history)±7% median
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction.